Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiyang Pill
- Development stage
- Preclinical
- Administration
- Oral
01
Overview
Yiyang Pill is an oral intervention currently undergoing a randomized controlled double-blind clinical study. It is being investigated for its potential to address cardiovascular adverse reactions that occur following TSH inhibition treatment after thyroid cancer operation. Given the context of the clinical trial being run by Chinese institutions and the name format, it is likely a Traditional Chinese Medicine (TCM) formulation.
- Other names
- Yiyang益养丸
02
Targets
ESR1 (ERα)IL-6 (Interleukin 6)NOS3 (eNOS)PDE5 (Phosphodiesterase 5A)
Beyond the preview
Go deeper on Yiyang Pill.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yiyang Pill.